Bottom Line Here's what the data tells us: GI side effects dominate: nausea, diarrhea, vomiting, constipation Higher efficacy = slightly higher side effects at maximum doses Glucagon adds benefits: liver fat reduction, increased energy expenditure Slow escalation helps: 20+ week titration minimizes symptoms Still investigational: Phase 3 trials ongoing, FDA decision expected 2025-2026 Sources Retatrutide Phase 2 Trial (Jastreboff et al., NEJM 2023) TRIUMPH Phase 3 Trial (ClinicalTrials.gov) ClinicalTrials.gov Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice
Though the exact mechanisms remain unclear, some researchers hypothesize that changes in body mass, blood flow, or metabolic processes could play a role in increasing clot risk
If the same occurs in obese T1D, these are desirable outcomes on their own
These gastrointestinal symptoms typically appear early in treatment and improve over time
European Journal of Applied Physiology 2005;95:431-435